Best Life Sciences Companies in Irvine, United States

Developer of therapeutics for gout, chronic kidney diseases, and oncology. The company's proprietary drug candidate includes AR882 which is used to decrease the level of uric acid in gout patients. It works by inhibiting urate transporter 1 (URAT1), an influx transporter protein present in kidneys.

Funding rounds

• Jun 2025Series E$153M
• Jul 2023Series D$75M
• Mar 2023Series B$15M
• Nov 2021Series B$26M

Founders & team

Litain YehCo-Founder & CEO

Investors

Guangrun Health Industry, Reichstein Biotech, Prime Eight Capital, Hlc Fund, HM Venture Partners, Reliant Tech

Tech stack

Animate.CssAosApple Icloud MailBootstrapBootstrap IconsCloudflare

Provider of an anti-clogging platform for surgical drainage devices. The technology that utilizes a magnetically driven Clearance Loop to proactively maintain blood flow to allow evacuation of blood and fluids from the chest cavity thus preventing Retained Blood syndrome. Retained Blood Syndrome (RBS) is the composite of drainage-related complications after cardiothoracic surgery, including hemothorax, pericardial tamponade, bloody pleural or pericardial effusions.It is used to resolve catheter clogging in multiple medical market segments, including urinary catheters, gastrointestinal catheters, and wound drainage.

Funding rounds

• Jul 2025Series D$2.1M
• Jun 2024Series D$2.3M
• Aug 2020Series D$7.5M
• May 2019Series D$7.6M

Founders & team

Edward BoyleFounderHannah BeathardChief Executive Officer

Investors

Oregon Venture Fund, Aphelion Capital, California Technology Ventures, RCT, Octane, Global Cardiovascular Innovation Center

Tech stack

Apache Http ServerCart FunctionalityCdnjsCloudflareCloudflare Bot ManagementCore-Js

Provider of noninvasive tests to improve the early detection and treatment of bladder cancer for physicians and hematuria patients. They aim to transform the management of hematuria and enhance clinical decisions.

Funding rounds

• Mar 2026Series A$4.5M

Founders & team

Christopher ThibodeauCEO

Manufacturer of minimally invasive medical devices for heart failure patients. The company develops solutions for individuals experiencing heart failure symptoms. It focuses on addressing the needs of medical professionals and patients. The company's devices aim to improve the lives of those affected by cardiac conditions.

Funding rounds

• Sep 2025Series B$11.6M

Founders & team

Wei GanFounder & CEO

Developer of medical device for the minimally invasive treatment of vascular disease. It offers Laguna Clot Retriever System and Malibu Aspiration Catheter System for minimally invasive solutions to treat arterial and venous thromboembolism.

Funding rounds

• May 2025Series A$10M
• Mar 2024Series A$5.7M
• Jun 2021Series A$6.2M

Founders & team

Sanjay ShrivastavaFounder & CEO

Developer of heart valve systems to treat valve regurgitation. It offers heart valve replacement technology combines balloon-expandable valve systems for stenosis and self-expandable technologies for superior heart valve performance and to treat aortic regurgitation.

Funding rounds

• Dec 2025Series A$3.2M

Founders & team

Gilbert MadridCEO

Investors

Hyfinity Investments

Developer of T-cell therapeutics for cancer treatment. The company's lead product candidate BAFF-R CAR-T was constructed which is found to kill lymphomas and leukemias in-vitro as well as established lymphoma in vivo. The product is under IND enabling study for its further development.

Developer of cell therapies for age-related and disease-related immune deficits. It offers a STEM product line developed from human stem cells that secrete immune modulators for treating muscle atrophy in patients with knee osteoarthritis and muscle performance in seniors with obesity and muscle weakness.

Developer of non-invasive diagnostic test solutions for the treatment of cancer. The company has developed DetermaRx for non-squamous NSCLC and DetermaRx + EGFR for early-stage NSCLC testing. The platform analyzes both blood and urine samples for specific cancer biomarkers using an algorithm to compare gene expression patterns with a database of gene expression patterns of known cancers. It can be used to identify lung, breast, and bladder cancer.

Funding rounds

• Feb 2025Post IPO$21.7M
• Oct 2024Post IPO$10.2M
• Apr 2024Post IPO$15.8M
• 2021Post IPO—

Founders & team

Ron AndrewsCEO & President

Investors

SG Americas Securities, Pura Vida Investments, Connor, Clark & Lunn Financial Group, Maven, Geode Capital, MetLife

Tech stack

WordpressMysqlPhpBootstrapDraftpress HfcmContact Form 7

Developer of stroke rehabilitation systems. The company has developed personalized neurorehabilitation devices which includes FitMi a full-body neuro-rehab device, and Musicglove - a music-based hand therapy

Provider of therapeutics solution for organ or cellular transplantation in autoimmune and neurodegenerative disease. The company targets the CD40L pathway and anti-CD40 Ligand (CD40L) pathway antibodies. The company lead product is AT-1501, for pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation. The other lead product is AT-2001 to target autoimmune indications.

Developer of the device for 3D imaging of biological samples. The product Mesoscale imaging system used for tissue clearing, light-sheet imaging, computational 3D, and machine-learning-based image analysis for brain and complex organs. The system consists of the imaging chamber, specimen holder, safety collar, and objective adapter.